Methamphetamine-induced alterations in dopamine transporter function

Brain Research

Volumn 782, Issue 1-2, 1998, Pages 219-227

  Bennett, Barbara A ^a   Hollingsworth, Charlotte K ^a   Martin, R Shayn ^a   Harp, Jill J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Methamphetamine; Midbrain culture; Release; Transporter

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMPHETAMINE; COCAINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; NOMIFENSINE; PROCAINE; RACLOPRIDE; VERATRIDINE;

ADAPTATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FETUS; MESENCEPHALON; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION;

ANIMALS; CARRIER PROTEINS; CELLS, CULTURED; COCAINE; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; KINETICS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MESENCEPHALON; METHAMPHETAMINE; NERVE TISSUE PROTEINS; NEURONS; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; SALICYLAMIDES;

EID: 0032567775     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01281-X     Document Type: Article

References (54)

1. Azzaro A.J., Rutledge C.O. Selectivity of release of norepinephrine, dopamine and 5-hydroxytryptamine by amphetamine in various regions of rat brain. Biochem. Pharmacol. 22:1973;2801-2813.
2. B.A. Bennett, C.E. Hyde, J.R. Pecora, J.E. Clodfelter, Differing neurotoxic potencies of methamphetamine, mazindol, and cocaine in mesencephalic cultures, J. Neurochem., (1993) 1444-1452.
3. Bennett B.A., Paris J.M., Pecora J.R. Stimulant-induced alterations in dopaminergic and serotonergic function in fetal raphe neurons. Brain Res. Bull. 31:1993;471-476.
4. Bennett B.A., Rusyniak D.E., Hollingsworth C.K. HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. Brain Res. 705:1995;168-176.
5. Besson M.J., Cheramy A., Feltz P., Glowinski J. Release of newly synthesized dopamine from dopamine-containing terminals in the striatum of the rat. Proc. Natl. Acad. Sci. USA. 62:1969;741-748.
6. Bottenstein J.E., Sato G.H. Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc. Natl. Acad. Sci. USA. 76:1979;514-517.
7. Buening M.K., Gibb J.W. Influence of methamphetamine and neuroleptic drugs on tyrosine hydroxylase activity. Eur. J. Pharmacol. 26:1974;30-34.
8. Castaneda E., Becker J.B., Robinson T.E. The long-term effects of repeated amphetamine treatment in vivo on amphetamine, KCl and electrical stimulation evoked striatal dopamine release in vitro. Life Sci. 42:1988;2447-2456.
9. Clausing P., Gough B., Holson R.R., Slikker W. Jr., Bowyer J.F. Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. J. Pharmacol. Exp. Ther. 274:1995;614-621.
10. C.E. Cook, A.R. Jeffcoat, M. Perez-Reyes, B.M. Sadler, J.M. Hill, W.R. White, S. McDonald, Plasma levels of methamphetamine after smoking of methamphetamine hydrochloride, in: L.S. Harris (Ed.), Problems of Drug Dependence 1990: Proceedings of the 52nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, National Institute on Drug Abuse Research Monograph 105, Washington, DC, 1991, pp. 578-579.
11. Coyle J.T., Snyder S.H. Catrecholamine uptake by synaptosomes in homogenates of rat brain: Stereospecificity in different areas. J. Pharmacol. Exp. Ther. 170:1969;221-231.
12. Cubells J.F., Rayport S., Rajendran G., Sulzer D. Methamphetamine neurotoxicity involves vacuolization of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14:1994;2260-2271.
13. Ellison G., Eison M.S., Huberman H.S., Daniel F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science. 201:1978;276-278.
14. Fischer J.F., Cho A.K. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208:1979;203-209.
15. A.G. Gilman, L.S. Goodman, T.W. Rall, F. Murad, The Pharmacological Basis of Therapeutics, MacMillan, New York, 1985.
16. Giros B., el Mestikawy S., Bertrand L., Caron M.G. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett. 295:1991;149-154.
17. Giros B., el Mestikawy S., Godinot N., Zheng K., Han H., Yang-Feng T., Caron M.G. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol. Pharmacol. 42:1992;383-390.
18. Golden G.S. Prenatal development of the biogenic amine systems of the mouse brain. Dev. Biol. 33:1973;300-311.
19. Harris J.E., Baldessarini R.J. The uptake of 3H-dopamine by homogenates of rat corpus striatum: Effects of cations. Life Sci. 13:1973;303-312.
20. Horn A.S., Coyle J.T., Snyder S.H. Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons. Mol. Pharmacol. 7:1971;66-80.
21. Iversen L.L. Catecholamine uptake processes. Brain Med. Bull. 29:1973;130-135.
22. 3H]dopamine uptake in vitro in rat nucleus accumbens but not in striatum. Brain Res. 531:1990;338-341.
23. Klawans H.L., Margolin D.I. Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders. Arch. Gen. Psychiatry. 32:1975;725-732.
24. Kogan F.J., Nichols W.K., Gibb J.W. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36:1976;363-371.
25. Kolta M.G., Shreve P., De Souza V., Uretsky N.J. Time course of the development of the enhanced behavioral and biochemical responses to amphetamine after pretreatment with amphetamine. Neuropharmacology. 24:1985;823-829.
26. Kontur P.J., Won L.A., Hoffmann P.C., Heller A. Survival of developing dopaminergic neurons in reaggregate tissue culture following treatment with methamphetamine. Neurosci. Lett. 129:1991;254-258.
27. R. Kuczenski, Biochemical actions of amphetamine and other stimulants, in: I. Creese (Ed.), Stimulants: Neurochemical, Behavioral and Clinical Perspectives, Raven, New York, 1983.
28. 3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem. Pharmacol. 31:1982;983-992.
29. Lim D.K., Yu Z.J., Hoskins B., Rockhold R.W., Ho I.K. Effects of acute and subacute cocaine administration on the CNS dopaminergic system in Wistar-Kyoto and spontaneously hypertensive rats: III. Dopamine uptake. Neurochem. Res. 15:1990;629-634.
30. Loren I., Bjorklund A., Falck B., Lindvall O. An improved histofluorescence procedure for freeze-dried paraffin-embedded tissue based on combined formaldehyde-glyoxylic acid perfusion with high magnesium content and acid pH. Histochemistry. 49:1976;177-192.
31. Marcusson J.O., Ross S.B. Binding of some antidepressants to the 5-hydroxytryptamine transporter in brain and platelets. Psychopharmacology. 102:1990;145-155.
32. 3H]-dopamine uptake in the nucleus accumbens, striatum and frontal cortex in rats. J. Pharmacol. Exp. Ther. 270:1994;133-144.
33. M. Miller, Trends and patterns of methamphetamine smoking in Hawaii, in: L.S. Harris (Ed.), Problems of Drug Dependence 1990: Proceedings of the 52nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, National Institute on Drug Abuse Research Monograph 105, Washington, DC, 1991, pp. 72-83.
34. Missale C., Castelletti L., Govoni S., Spano P.F., Trabucchi M., Hanbauer I. Dopamine uptake is differentially regulated in rat striatum and nucleus accumbens. J. Neurochem. 45:1985;51-56.
35. Nakayama M., Koyama T., Yamashita I. Long-lasting decrease in dopamine uptake sites following repeated administration of methamphetamine in the rat striatum. Brain Res. 601:1993;209-212.
36. S.L. Povlock, S.M. Meiergerd, J.O. Schenk, Kinetic mechanisms of the dopamine transporter: A comparison with other biogenic amine transporters, in: T.W. Stone (Ed.), CNS Neurotransmitters and Neuromodulators of Dopamine, CRC Press, Boca Raton, FL, 1996, pp. 21-40.
37. Raiteri M., Bertollini A., Angelini F., Levi G. D-Amphetamine as a releaser or reuptake inhibitor of biogenic amines in synaptosomes. Eur. J. Pharmacol. 34:1975;189-195.
38. Raiteri M., del Carmine R., Bertollini A., Levi G. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur. J. Pharmacol. 41:1977;133-143.
39. Ricaurte G.A., Schuster C.R., Seiden L.S. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 193:1980;153-163.
40. Robinson T.E., Becker J.B. Behavioral sensitization is accompanied by an enhancement in amphetamine-stimulated dopamine release from striatal tissue in vitro. Eur. J. Pharmacol. 85:1982;253-254.
41. Robinson T.E., Becker J.B., Presty S.K. Long-term facilitation of amphetamine-induced rotational behavior and striatal dopamine release produced by a single exposure to amphetamine: sex differences. Brain Res. 253:1982;231-241.
42. Rutledge C.O. Effect of metabolic inhibitors and ouabain on amphetamine- and potassium-induced release of biogenic amines from isolated brain tissue. Biochem. Pharmacol. 27:1978;511-516.
43. Ryan L.J., Linder J.C., Martone M.E., Groves P.M. Histological and ultrastructural evidence that D-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res. 518:1990;67-77.
44. Segal D.S., Kuczenski R. In vivo microdialysis reveals a diminished amphetamine-induced DA response corresponding to behavioral sensitization produced by repeated amphetamine pretreatment. Brain Res. 571:1992;330-3375.
45. Seiden L.S., Commins D.L., Vosmer G., Axt K., Marek G. Neurotoxicity in, dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections. Ann. New York Acad. Sci. 77:1986;161-172.
46. Seutin V., Verbanck P., Massotte L., Dresse A. Acute amphetamine-induced subsensitivity of A10 dopamine autoreceptors in vitro. Brain Res. 558:1991;141-144.
47. Sulzer D., Pothos E., Sung H.M., Maidment N.T., Hoebel B.G., Rayport S. Weak base model of amphetamine action. Ann. New York Acad. Sci. 654(28):1992;525-528.
48. Sulzer D., Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron. 5:1990;797-808.
49. Usdin T.B., Mezey E., Chen C., Brownstein M.J., Hoffman B.J. Cloning of the cocaine-sensitive bovine dopamine transporter. Proc. Natl. Acad. Sci. USA. 88:1991;11168-11171.
50. Wagner G.C., Ricaurte G.A., Seiden L.S., Schuster C.R., Miller R.J., Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181:1980;151-160.
51. Wichems C.H., Hollingsworth C.K., Bennett B.A. Release of serotonin induced by 3,4-methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in fetal raphe neurons: further evidence for calcium-independent mechanisms of release. Brain Res. 695:1995;10-18.
52. Wolf M.E., White F.Y., Hu X. MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine. J. Neurosci. 14:1994;1735-1745.
53. Yamada S., Yokoo H., Nishi S. Changes in sensitivity of dopamine autoreceptors in rat striatum after subchronic treatment with methamphetamine. Eur. J. Pharmacol. 205:1991;43-47.
54. 3H]dopamine. Neuropharmacology. 29:1990;475-486.